AcroCyte Featured in Weill Cornell Medicine HemOnc Seminar Talks : Liquid Biopsy Series
News July 8,2026

AcroCyte Therapeutics was honored to be invited to the HemOnc Seminar Talks – Liquid Biopsy Series hosted by Weill Cornell Medicine on June 22, 2026. During the session, Dr. Ying C. Chang, CEO of AcroCyte Therapeutics, shared forward-looking insights into the evolution of functional liquid biopsy technologies.

Liquid biopsy has significantly advanced cancer detection and disease monitoring. However, a critical challenge in precision oncology remains: moving beyond detection toward a functional understanding of tumor biology and therapeutic response.

In her presentation, Dr. Chang introduced AcroCyte’s proprietary R³CE® technology, which enables the rapid expansion of patient-derived circulating tumor cells (CTCs) into functional 3D tumor models. This breakthrough platform opens new possibilities for translational oncology research, drug discovery, and precision medicine.

The seminar further highlighted AcroCyte’s commitment to advancing next-generation functional liquid biopsy solutions through its innovative scaffold-free 3D cell culture technology.

 

Key Highlights

  • Rapid expansion of patient-derived CTCs into functional 3D tumor models
  • Proprietary scaffold-free R³CE® technology for functional cell culture
  • Broad applications in translational oncology, drug discovery, and precision medicine
  • Driving the next generation of functional liquid biopsy innovation

 

Watch the Seminar

Learn more about Dr. Ying C. Chang’s presentation at the Weill Cornell Medicine HemOnc Seminar Series.

Watch the full presentation: From Detection to Function: Advancing Liquid Biopsies with R³CE® CTC Models



                 

Privacy Preference Center

1. Who We Are
At AcroCyte Therapeutics Inc. (“AcroCyte”, “we”, “our”), we are committed to maintaining the trust and confidence of all visitors to our website, www.acrocyte.com. We value your privacy and want you to be clear about how we handle your data. In particular, AcroCyte is not in the business of selling, renting, or trading email lists with other companies for marketing purposes. This Privacy Policy outlines when and why we collect personal information, how we use it, the limited conditions under which we may disclose it to others, and how we keep it secure.

2. Information We Collect & How We Use It
Contact Forms & Business Inquiries
When you contact us via the forms on our website (such as the "Contact Us" page), we collect the professional information you provide, including your name, email address, phone number, company name, job title, industry, area of interest, and the content of your inquiry.

  • Purpose: We use this data solely to communicate with you, verify your identity, answer your technical or business questions, and provide information about our products and services relevant to your request.
  • Marketing Communications: We will only send you newsletters, product updates, or promotional materials if you have explicitly opted in by checking the relevant box (e.g., "Yes, I'd like to receive updates about AcroCyte news and breakthroughs"). You may unsubscribe from these communications at any time by clicking the "unsubscribe" link in our emails.

Cookies
We use cookies to support essential website functionality and to provide a better user experience. You can choose to disable or delete cookies at any time through your internet browser settings; however, this may limit your ability to use certain features of our website.

3. Third-Party Services & Data Processors

Google Analytics
We use Google Analytics to collect standard internet log information and details of visitor behavior patterns. This helps us understand website traffic and improve performance. This information is processed in a way that does not identify anyone personally. We do not make, and do not allow Google to make, any attempt to find out the identities of those visiting our website.

Google reCAPTCHA
To protect our website forms from spam and automated abuse, we use the reCAPTCHA service provided by Google. This service analyzes behavior to distinguish between humans and bots. Your use of reCAPTCHA is subject to Google’s Privacy Policy and Terms of Service.

Service Providers
We may share your information with trusted third-party service providers who assist us in operating our website, conducting our business, or serving our users (e.g., email delivery services, CRM systems, or hosting providers), so long as those parties agree to keep this information confidential.

4. International Data Transfers
AcroCyte operates globally with offices in Taiwan and the United States. Please be aware that your personal information may be transferred to, stored, and processed in a country other than the one in which you reside. By providing us with your information, you acknowledge and agree to this transfer, storage, or processing. We take all reasonable steps to ensure that your data is treated securely and in accordance with this policy.

5. Data Retention
We retain your personal information only for as long as is necessary to fulfill the purposes for which it was collected, including for the purposes of satisfying any legal, accounting, or reporting requirements. When data is no longer needed, we will securely delete or anonymize it.

6. Access to Your Personal Information & Your Rights
You have the right to request access to, correction of, or deletion of any personal data that we hold about you. Depending on your jurisdiction (such as under the GDPR), you may also have the right to restrict processing, object to processing, or request data portability. To make such a request, please contact our Privacy Team at [info@acrocyte.com].

7. Changes to Our Privacy Policy
We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. The most current version will always be available on our website. By continuing to access or use our website after those changes become effective, you agree to be bound by the revised Privacy Policy.